×
About 914 results
Association of Testosterone Therapy With Risk of Venous Thromboembolism Among Men With and Without Hypogonadism
https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2754091
JAMA Internal Medicine; Rob F. Walker, et al

Nov 30th, 2019 - Testosterone therapy is increasingly prescribed in patients without a diagnosis of hypogonadism. This therapy may be associated with increased risk of venous thromboembolism (VTE) through several mechanisms, including elevated hematocrit levels, which increase blood viscosity.

FDA takes second action under international collaboration, approves new treatment option for patients with chronic lymphocytic leukemia
https://www.fda.gov/news-events/press-announcements/fda-takes-second-action-under-international-collaboration-approves-new-treatment-option-patients
FDA

Nov 24th, 2019 - Today, as part of Project Orbis, a collaboration with the Australian Therapeutic Goods Administration (TGA) and Health Canada, the U.S. Food and Drug Administration granted supplemental approval to Calquence (acalabrutinib) for the treatment of adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This new approved indication for Calquence provides a new treatment ...

FDA approves therapy to treat patients with relapsed and refractory mantle cell lymphoma supported by clinical trial results showing high response rate of tumor shrinkage
https://www.fda.gov/news-events/press-announcements/fda-approves-therapy-treat-patients-relapsed-and-refractory-mantle-cell-lymphoma-supported-clinical
FDA

Nov 16th, 2019 - The U.S. Food and Drug Administration granted accelerated approval to Brukinsa (zanubrutinib) capsules for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy.

Diffuse large B cell lymphoma
https://www.cancertherapyadvisor.com/home/decision-support-in-medicine/hematology/diffuse-large-b-cell-lymphoma/
Cancer Therapy Advisor; Thomas M. Habermann

Nov 13th, 2019 - Diffuse large B-cell lymphoma (DLBCL) is an aggressive lymphoma that is potentially curable. DLBCL is the most common non-Hodgkin lymphoma (NHL) representing about 30% of all cases of NHL in the United States of America (USA) and Europe. There are over 76 different types of lymphoma. It is essential to establish the correct histological diagnosis prior to treatment.

Diffuse Large B-Cell Lymphoma: ESMO Clinical Practice Guidelines
https://www.esmo.org/Guidelines/Haematological-Malignancies/Diffuse-Large-B-Cell-Lymphoma
Annals of Oncology; Tilly H et al

Nov 13th, 2019 - Diffuse large B-cell lymphoma is relatively common and represents 30%–58% of non-Hodgkin’s lymphomas. The updated ESMO Clinical Practice Guidelines provide information on the current management of diffuse large B-cell lymphoma including recommendations for screening and diagnosis, staging and risk assessment and stage-matched therapeutic strategies including specific recommendations for young a...

FDA approves first therapy to treat patients with rare blood disorder
https://www.fda.gov/news-events/press-announcements/fda-approves-first-therapy-treat-patients-rare-blood-disorder
FDA FDA

Nov 9th, 2019 - Today the U.S. Food and Drug Administration granted approval to Reblozyl (luspatercept–aamt) for the treatment of anemia (lack of red blood cells) in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions.

Diffuse Large B-Cell Lymphoma
https://www.lymphoma.org/aboutlymphoma/nhl/dlbcl/
Lymphoma Research Foundation;

Nov 6th, 2019 - Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) in the United States and worldwide, accounting for about 22 percent of newly diagnosed cases of B-cell NHL in the United States. More than 18,000 people are diagnosed with DLBCL each year.

High Expression of DOCK2 Indicates Good Prognosis in AML
https://www.jcancer.org/v10p6088.htm
Journal of Cancer; Hu N, et al

Oct 14th, 2019 - DOCK family proteins are evolutionarily conserved guanine nucleotide exchange factors for Rho GTPase with different cellular functions. It has been demonstrated that DOCK1 had adverse prognostic effect in acute myeloid leukemia (AML).

U.S. FDA Approves XARELTO® (rivaroxaban) to Help Prevent Blood Clots in Acutely Ill Medical Patients
https://www.jnj.com/u-s-fda-approves-xarelto-rivaroxaban-to-help-prevent-blood-clots-in-acutely-ill-medical-patients

Oct 13th, 2019 - he Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved XARELTO® (rivaroxaban) for the prevention of venous thromboembolism (VTE), or blood clots, in hospitalized acutely ill medical patients at risk for thromboembolic complications who are not at high risk of bleeding. With the approval of this new indication, XAREL...

Anticoagulation: Updated Guidelines for Outpatient Management
https://www.aafp.org/afp/2019/1001/p426.html
American Family Physician;

Sep 30th, 2019 - Anticoagulation therapy is recommended for preventing, treating, and reducing the recurrence of venous thromboembolism, and preventing stroke in persons with atrial fibrillation. Direct oral anticoagulants are first-line agents for eligible patients for treating venous thromboembolism and preventing stroke in those with nonvalvular atrial fibrillation. Vitamin K antagonists are recommended for ...

FDA approves daratumumab for transplant-eligible multiple myeloma
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daratumumab-transplant-eligible-multiple-myeloma

Sep 25th, 2019 - On September 26, 2019, the Food and Drug Administration approved daratumumab (DARZALEX, Janssen) for adult patients with multiple myeloma in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant (ASCT).

Screening and Management of Bleeding Disorders in Adolescents With Heavy Menstrual Bleeding: ACOG COMMITTEE OPINION, Number 785
https://www.acog.org/Clinical-Guidance-and-Publications/Committee-Opinions/Committee-on-Adolescent-Health-Care/Screening-and-Management-of-Bleeding-Disorders-in-Adolescents-With-Heavy-Menstrual-Bleeding

Aug 21st, 2019 - Heavy menstrual bleeding is defined as excessive menstrual blood loss that interferes with a woman's physical, social, emotional, or material quality of life. If obstetrician–gynecologists suspect that a patient has a bleeding disorder, they should work in coordination with a hematologist for laboratory evaluation and medical management. Evaluation of adolescent girls who present with heavy men...

Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies Treatment (PDQ®)–Health Professional Version
https://www.cancer.gov/types/leukemia/hp/child-aml-treatment-pdq

Aug 19th, 2019 - Treatments for children with acute myeloid leukemia and myeloid malignancies include combination chemotherapy, stem cell transplantation, and targeted therapy. Other drug therapy and supportive care is also used. Get detailed information for these diseases in this clinician summary.

U.S. FDA Approves INREBIC® (Fedratinib) as First New Treatment in Nearly a Decade for Patients With Myelofibrosis
https://ir.celgene.com/press-releases/press-release-details/2019/US-FDA-Approves-INREBIC-Fedratinib-as-First-New-Treatment-in-Nearly-a-Decade-for-Patients-With-Myelofibrosis/default.aspx

Aug 16th, 2019 - Celgene Corporation (NASDAQ: CELG) today announced the U.S. Food and Drug Administration (FDA) has approved INREBIC® (fedratinib) for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.1 “The approval of INREBIC is another important milestone for Celgene and underscores our commitment ...

Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer
https://ascopubs.org/doi/full/10.1200/JCO.19.01461

Aug 4th, 2019 - PURPOSE To provide updated recommendations about prophylaxis and treatment of venous thromboembolism (VTE) in patients with cancer. METHODS PubMed and the Cochrane Library were searched for randomized controlled trials (RCTs) and meta-analyses of RCTs published from August 1, 2014, through December 4, 2018. ASCO convened an Expert Panel to review the evidence and revise previous recommenda...

Use of Antibiotics and Risk of Cancer: A Systematic Review and Meta-Analysis of Observational Studies
https://www.mdpi.com/2072-6694/11/8/1174
Cancers Petrelli, F. et. al.

Jul 30th, 2019 - The association between antibiotic use and risk of cancer development is unclear, and clinical trials are lacking. We performed a systematic review and meta-analysis of observational studies to assess the association between antibiotic use and risk of cancer. PubMed, the Cochrane Library and EMBASE were searched from inception to 24 February 2019 for studies reporting antibiotic use and subsequ...

FDA takes action to protect patients from risk of certain textured breast implants; requests Allergan voluntarily recall certain breast implants and tissue expanders from market
https://www.fda.gov/news-events/press-announcements/fda-takes-action-protect-patients-risk-certain-textured-breast-implants-requests-allergan

Jul 23rd, 2019 - The U.S. Food and Drug Administration today took significant action to protect women from breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) by requesting that Allergan, the manufacturer of a specific type of textured implant, recall specific models of its textured breast implants from the U.S. market due to the risk of BIA-ALCL. Following the agency’s request, Allergan has not...

FDA Approves Pfizer’s Biosimilar, Ruxience™ (Rituximab-pvvr), For Certain Cancers And Autoimmune Conditions
https://www.pfizer.com/news/press-release/press-release-detail/fda_approves_pfizer_s_biosimilar_ruxience_rituximab_pvvr_for_certain_cancers_and_autoimmune_conditions

Jul 22nd, 2019 - Pfizer Inc. (NYSE:PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) has approved RUXIENCE™ (rituximab-pvvr), a biosimilar to Rituxan® (rituximab),1 for the treatment of adult patients with non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL), and granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA).2 “Biosimilars like RUXIENCE h...

Bayer Statement on Voluntary Recall of Two Lots of Kogenate FS Antihemophilic Factor (Recombinant) in the United States
https://www.drugs.com/fda/bayer-statement-voluntary-recall-two-lots-kogenate-fs-antihemophilic-factor-recombinant-united-14291.html

Jul 18th, 2019 - Bayer is voluntarily recalling two lots of Kogenate FS antihemophilic factor (recombinant) 2000 IU vials in the United States to the patient level. Certain vials from these two lots that were labeled as Kogenate FS actually contain the FVIII hemophilia A treatment, Jivi antihemophilic factor (recombinant) PEGylated-aucl 3000 IU. The U.S. is the only country where affected products were distribu...

Researchers Find Simple Way to Predict and Prevent Dangerous Blood Clots in Patients Treated for Multiple Myeloma
https://www.nccn.org/about/news/newsinfo.aspx?NewsID=1591

Jul 17th, 2019 - New research from the Hutchinson Institute for Cancer Outcomes Research (HICOR)—which is based at Fred Hutchinson Cancer Research Center—along with the University of Washington and the Seattle Cancer Care Alliance, identifies a simple way to help cancer doctors caring for patients with multiple myeloma to predict blood clots in order to take preventive action. The researchers established a set...

AGA Guideline on the Laboratory Evaluation of Functional Diarrhea and Diarrhea-Predominant Irritable Bowel Syndrome in Adults (IBS-D)
https://www.gastrojournal.org/article/S0016-5085(19)41083-4/fulltext?referrer=https%3A%2F%2Fwww.jwatch.org%2Fna49679%2F2019%2F08%2F09%2Ftesting-functional-diarrhea-and-diarrhea-predominant

Jul 10th, 2019 - This document presents the official recommendations of the American Gastroenterological Association (AGA) on the Laboratory Evaluation of Functional Diarrhea and Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) in Adults. The guideline was developed by the AGA’s Clinical Practice Guideline Committee and approved by the AGA Governing Board. These Guidelines should expire in 5 years. The ...

FDA approves new treatment for refractory multiple myeloma
https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-refractory-multiple-myeloma

Jul 2nd, 2019 - Today, the U.S. Food and Drug Administration granted accelerated approval to Xpovio (selinexor) tablets in combination with the corticosteroid dexamethasone for the treatment of adult patients with relapsed refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is resistant to several other forms of treatment, including at least two proteasome inhib...

Acute Myeloid Leukemia - AML | ARUPConsult Lab Test Selection
https://arupconsult.com/content/acute-myeloid-leukemia

Jun 30th, 2019 - Acute myeloid leukemias (AMLs) are a heterogeneous group of disorders characterized by the clonal expansion of myeloid blasts (eg, undifferentiated myeloid precursors) in the peripheral blood, bone marrow, and/or other tissues, which results in impaired hematopoiesis and bone marrow failure. 1, 2, 3, 4 AML is the most common acute leukemia in adults (~80% of leukemia cases) and accounts for the...

Dova Pharmaceuticals Announces Fda Approval Of Supplemental New Drug Application For Doptelet® (Avatrombopag) For Treatment Of Chronic Immune Thrombocytopenia (ITP)
http://investors.dova.com/news-releases/news-release-details/dova-pharmaceuticals-announces-fda-approval-supplemental-new

Jun 26th, 2019 - Dova Pharmaceuticals, Inc. (NASDAQ: DOVA), a pharmaceutical company focused on acquiring, developing and commercializing drug candidates for diseases where there is a high unmet need, today announced the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) that expands the use of DOPTELET (avatrombopag) to include the treatment of thrombocytopenia in adul...

ASCO 2019 Report — Hematologic Malignancy Highlights
https://www.jwatch.org/na49398/2019/06/20/asco-2019-report-hematologic-malignancy-highlights
Williams, M. et. al.

Jun 19th, 2019 - At this year's meeting of the American Society of Clinical Oncology (ASCO 2019), held May 31 to June 4 in Chicago, investigators discussed the latest findings in cancer research. The editors of NEJM Journal Watch Oncology and Hematology were on hand to report highlights of the conference. Here, Michael E. Williams, MD, ScM, reviews key presentations on new treatments for patients with multiple ...

Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology
https://jnccn.org/view/journals/jnccn/17/6/article-p721.xml
Journal of the National Comprehensive Cancer Network;

Jun 14th, 2019 - Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States. Recent advances have resulted in an expansion of treatment options for AML, especially concerning targeted therapies and low-intensity regimens. This portion of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guid...

FDA Approves REVLIMID® (Lenalidomide) In Combination With Rituximab For the Treatment of Adult Patients with Previously Treated Follicular Lymphoma or Marginal Zone Lymphoma
https://ir.celgene.com/press-releases/press-release-details/2019/FDA-Approves-REVLIMID-Lenalidomide-In-Combination-With-Rituximab-For-the-Treatment-of-Adult-Patients-with-Previously-Treated-Follicular-Lymphoma-or-Marginal-Zone-Lymphoma/default.aspx

May 27th, 2019 - Celgene Corporation (NASDAQ: CELG) today announced the U.S. Food and Drug Administration (FDA) approved REVLIMID® (lenalidomide) in combination with a rituximab product (R²) for the treatment of adult patients with previously treated follicular lymphoma (FL) or marginal zone lymphoma (MZL) following Priority Review designation. This is the first FDA-approved combination treatment regimen for pa...

FDA alerts hospitals, laboratories and health care professionals about recall of Beckman Coulter blood test analyzers due to risk of inaccurate platelet analyzing results
https://www.fda.gov/news-events/press-announcements/fda-alerts-hospitals-laboratories-and-health-care-professionals-about-recall-beckman-coulter-blood

May 22nd, 2019 - The U.S. Food and Drug Administration is alerting hospitals, laboratories and providers of a Class 1 recall of Beckman Coulter DxH 800, DxH 600 and DxH 900 hematology analyzers—devices that run blood tests to help providers diagnose diseases and conditions such as anemia (low red blood cell or hemoglobin count), infections, blood clotting problems, blood cancers and immune system disorders. Thi...

FDA approves first anticoagulant (blood thinner) for pediatric patients to treat potentially life-threatening blood clots
https://www.fda.gov/news-events/press-announcements/fda-approves-first-anticoagulant-blood-thinner-pediatric-patients-treat-potentially-life-threatening

May 15th, 2019 - The U.S. Food and Drug Administration today approved Fragmin (dalteparin sodium) injection, for subcutaneous use, to reduce the recurrence of symptomatic venous thromboembolism (VTE) in pediatric patients one month of age and older. VTE can include deep vein thrombosis (blood clot in the deep veins of the leg) and pulmonary embolism (blood clot in the lungs), which can lead to death.

Daiichi Sankyo Announces Outcome of FDA Oncologic Drugs Advisory Committee Meeting to Review FLT3 Inhibitor Quizartinib for the Treatment of Patients with Relapsed/Refractory FLT3-ITD AML
https://www.daiichisankyo.com/media_investors/media_relations/press_releases/detail/007017.html

May 13th, 2019 - Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced the outcome of the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) to discuss the company’s New Drug Application (NDA) for quizartinib for the treatment of adults with relapsed/refractory FLT3-ITD acute myeloid leukemia (AML). Three committee members voted yes and 8 committee m...

About TIBSOVO® (ivosidenib) 250 mg tablets IDH1 Testing and Mechanism of Action
https://www.tibsovopro.com/about-tibsovo/

May 9th, 2019 - TIBSOVO Ivosidenib targets the mutant IDH1 enzyme in R/R AML Learn more about IDH1 testing and the mechanism of action. Visit the site to view full prescribing information, including boxed warning.TIBSOVO is indicated for the treatment of acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation.

Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline
https://ascopubs.org/doi/10.1200/JCO.18.02096

May 9th, 2019 - PURPOSE To provide evidence-based recommendations on the treatment of multiple myeloma to practicing physicians and others. METHODS ASCO and Cancer Care Ontario convened an Expert Panel of medical oncology, surgery, radiation oncology, and advocacy experts to conduct a literature search, which included systematic reviews, meta-analyses, randomized controlled trials, and some phase II studi...

Ivosidenib Approved by FDA for Frontline IDH1+ AML
https://www.targetedonc.com/news/ivosidenib-approved-by-fda-for-frontline-idh1-aml

May 1st, 2019 - Single-agent ivosidenib (Tibsovo) has received FDA approval for the first-line treatment of adult patients with IDH1-mutant acute myeloid leukemia (AML), as detected by an FDA-approved test, who are ≥75 years old or are ineligible to receive intensive chemotherapy.

FDA approves ivosidenib as first-line treatment for AML with IDH1 mutation
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ivosidenib-first-line-treatment-aml-idh1-mutation

May 1st, 2019 - On May 2, 2019, the Food and Drug Administration approved ivosidenib (TIBSOVO, Agios Pharmaceuticals, Inc.) for newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, in patients who are at least 75 years old or who have comorbidities that preclude the use of intensive induction chemotherapy.

Agios Announces FDA Approval of Supplemental New Drug Application (sNDA) for TIBSOVO® as Monotherapy for Newly Diagnosed Adult Patients with IDH1 Mutant Acute Myeloid Leukemia (AML) Not Eligible fo...
http://investor.agios.com/news-releases/news-release-details/agios-announces-fda-approval-supplemental-new-drug-application

May 1st, 2019 - Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) to update the U.S. Prescribing Information for TIBSOVO®, an isocitrate dehydrogenase-1 (IDH1) inhibitor, to include adult patients with newly diagnosed a...

Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2019
https://jnccn.org/view/journals/jnccn/17/5/article-p414.xml
Journal of the National Comprehensive Cancer Network;

Apr 30th, 2019 - An important factor in long-term survival of patients with acute lymphoblastic leukemia (ALL) is their response to front-line therapy. Relative to treatment outcomes in pediatric and young adult patients with ALL, prolonged survival rates for older adults, especially those aged >60 years, remain low at approximately 20%.1–3 In Philadelphia chromosome (Ph)−positive ALL, however, the difference i...

Autolus Therapeutics Receives FDA Orphan Drug Designation for AUTO3 for Treatment of Acute Lymphoblastic Leukemia
https://autolus.gcs-web.com/news-releases/news-release-details/autolus-therapeutics-receives-fda-orphan-drug-designation-auto3

Apr 22nd, 2019 - Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, announced that the United States Food and Drug Administration (FDA) has granted orphan drug designation to autologous enriched T-cells genetically modified with a retroviral vector to express two chimeric antigen receptors target...

FDA grants fast track, orphan drug designations to APR-246 for myelodysplastic syndrome
https://www.healio.com/hematology-oncology/myeloproliferative-neoplasms/news/online/%7B1dd18005-dfc3-4413-ac65-6a84a3edc248%7D/fda-grants-fast-track-orphan-drug-designations-to-apr-246-for-myelodysplastic-syndrome

Apr 15th, 2019 - The FDA granted fast track designation to APR-246 for the treatment of patients with myelodysplastic syndrome who have TP53 mutations. The agency also granted orphan drug designation to APR-246 (Aprea Therapeutics) for treatment of myelodysplastic syndrome.

NCCN Flash Updates: NCCN Guidelines® and NCCN Compendium® for Acute Lymphoblastic Leukemia
https://www.nccn.org/about/news/ebulletin/ebulletindetail.aspx?ebulletinid=1612

Apr 14th, 2019 - NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Acute Lymphoblastic Leukemia. These NCCN Guidelines® are currently available as Version 1.2019

NCCN Flash Updates: NCCN Guidelines® and NCCN Compendium® for Hodgkin Lymphoma and Pancreatic Adenocarcinoma
https://www.nccn.org/about/news/ebulletin/ebulletindetail.aspx?ebulletinid=1613

Apr 14th, 2019 - NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and the Drugs & Biologics Compendium (NCCN Compendium®) for Hodgkin Lymphoma. These NCCN Guidelines® are currently available as Version 1.2019.

Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by t...
https://www.idsociety.org/globalassets/idsa/practice-guidelines/2019-asymptomatic-bacteriuria.pdf

Mar 20th, 2019 - Asymptomatic bacteriuria (ASB) is a common finding in many populations, including healthy women and persons with underlying urologic abnormalities. The 2005 guideline from the Infectious Diseases Society of America recommended that ASB should be screened for and treated only in pregnant women or in an individual prior to undergoing invasive urologic procedures.

Efficacy of Ibrutinib-Based Regimen in Chronic Lymphocytic Leukemia: A Systematic Review
https://www.thejh.org/index.php/jh/article/view/482/387
Sardar, M. et. al.

Mar 11th, 2019 - Ibrutinib has shown to have better efficacy than standard chemoimmunotherapy in del17 positive chronic lymphocytic leukemia (CLL) patients; however its role in del17 negative patients is less clear. We aim to evaluate the efficacy of ibrutinib-based regimens in CLL. Seven databases were searched in accordance with PRISMA statement guidelines using the following keywords: chronic lymphocytic leu...

FDA Briefing Document Oncologic Drugs Advisory Committee Meeting- Selinexor
https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM631806.pdf

Feb 25th, 2019 - Selinexor, an oral XPO1 inhibitor, is indicated in combination with dexamethasone, for the treatment of patients with relapsed refractory multiple myeloma (RRMM) who have received at least three prior therapies and whose disease is refractory to at least one proteasome inhibitor (PI), at least one immunomodulatory agent (IMiD), and an antiCD38 monoclonal antibody (mAb)

Cancer incidence in the Agricultural Health Study after 20 years of follow-up
https://link.springer.com/article/10.1007%2Fs10552-019-01140-y
Cancer Causes & Control; Lerro, C. et. al.

Feb 24th, 2019 - To evaluate cancer incidence in the Agricultural Health Study (AHS), a cohort of private pesticide applicators, their spouses, and commercial applicators, based on 12,420 cancers, adding 5,989 cancers, and 9 years of follow-up since last evaluation. Overall AHS cancer incidence was lower than the general population (SIRprivate = 0.91, CI 0.89–0.93; SIRspouse = 0.89, CI 0.86–0.92; SIRcommercial ...

Apixaban to Prevent Venous Thromboembolism in Patients with Cancer
https://www.nejm.org/doi/10.1056/NEJMoa1814468
The New England Journal of Medicine; Carrier, M. et. al.

Feb 20th, 2019 - Patients with active cancer have an increased risk of venous thromboembolism, which results in substantial morbidity, mortality, and health care expenditures. The Khorana score (range, 0 to 6, with higher scores indicating a higher risk of venous thromboembolism) has been validated to identify patients with cancer at elevated risk for this complication and may help select those who could benefi...

Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer
https://doi.org/10.1056/NEJMoa1814630
Khorana. A., et al

Feb 20th, 2019 - Ambulatory patients receiving systemic cancer therapy are at varying risk for venous thromboembolism. However, the benefit of thromboprophylaxis in these patients is uncertain. In high-risk ambulatory patients with cancer, treatment with rivaroxaban did not result in a significantly lower incidence of venous thromboembolism or death due to venous thromboembolism in the 180-day trial period. Dur...

Arterial thromboembolic events preceding the diagnosis of cancer in older persons
http://www.bloodjournal.org/content/133/8/781
Blood Havi, B. et. al.

Feb 20th, 2019 - Cancer patients face an increased risk of arterial thromboembolism; however, it is uncertain when this excess risk begins. This study evaluated the risk of arterial thromboembolism before cancer diagnosis. Using the population-based Surveillance Epidemiology and End Results-Medicare linked dataset, we identified 374 331 patients ≥67 years of age with a new primary diagnosis of breast, lung, pro...

Novo Nordisk receives US FDA approval of ESPEROCT® (turoctocog alfa pegol, N8-GP)
https://www.novonordisk.com/content/Denmark/HQ/www-novonordisk-com/en_gb/home/media/news-details.2235689.html

Feb 18th, 2019 - Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application for ESPEROCT® for the treatment of adults and children with haemophilia A. ESPEROCT® is the brand name for turoctocog alfa pegol, N8-GP. ESPEROCT® is indicated for use in adults and children with haemophilia A (congenital factor VIII deficiency) for routine prophylaxis to r...

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
http://www.bio-rad.com/en-us/corporate/newsroom/bio-rad-releases-first-fda-cleared-digital-pcr-system-test-for-monitoring-chronic-myeloid-leukemia-treatment-response?ID=Bio-Rad-Releases-Fir_1550252610

Feb 13th, 2019 - Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system ...

FDA approves daratumumab split-dosing regimen in multiple myeloma
https://www.healio.com/hematology-oncology/myeloma/news/online/%7B1716890b-f603-4c3f-9e03-dc86ffad3a27%7D/fda-approves-daratumumab-split-dosing-regimen-in-multiple-myeloma

Feb 12th, 2019 - The FDA approved a split-dosing regimen for daratumumab that will allow the first infusion to be administered over two consecutive days for patients with multiple myeloma, according to a press release from the drug’s manufacturer. The approval was based on data from the phase 1b EQUULEUS trial that showed comparable pharmacokinetic concentrations of daratumumab (Darzalex, Janssen Pharmaceutical...

U.S. FDA Approves DARZALEX® (daratumumab) Split-Dosing Regimen
https://www.janssen.com/us-fda-approves-darzalex-daratumumab-split-dosing-regimen

Feb 11th, 2019 - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved a split-dosing regimen for DARZALEX® (daratumumab), providing healthcare professionals and patients with multiple myeloma an option to split the first infusion over two consecutive days. The U.S. FDA approval is based on data from the Phase 1b EQUULEUS (MMY1001...

DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma
http://ascopubs.org/doi/full/10.1200/JCO.18.00915
Flinn, I. et. al.

Feb 10th, 2019 - Indolent non-Hodgkin lymphoma (iNHL) remains largely incurable and often requires multiple lines of treatment after becoming refractory to standard therapies. Duvelisib was approved by the Food and Drug Administration for relapsed or refractory (RR) chronic lymphocytic leukemia or small lymphocytic lymphoma (SLL) and RR follicular lymphoma (FL) after two or more prior systemic therapies. On the...

Adult Acute Myeloid Leukemia (AML) Treatment (PDQ®)–Health Professional Version
https://www.cancer.gov/types/leukemia/hp/adult-aml-treatment-pdq

Feb 7th, 2019 - Acute myeloid (myelogenous) leukemia (AML) treatment options include chemotherapy, radiation therapy, stem cell transplant, and other medications. Cytogenetic analysis helps predict treatment outcomes. Get detailed information about AML risk factors in this summary for clinicians.

Breast Implant Associated-Anaplastic Large Cell Lymphoma (BIA-ALCL) - Letter to Health Care Providers
https://www.fda.gov/MedicalDevices/Safety/LetterstoHealthCareProviders/ucm630863.htm
FDA

Feb 5th, 2019 - The Food and Drug Administration (FDA) wants to increase awareness about an association between all breast implants, regardless of filling or texture, and Breast Implant Associated- Anaplastic Large Cell Lymphoma (BIA-ALCL). The FDA received reports indicating that patients with breast implants have an increased risk of developing this disease within the scar capsule adjacent to the implant.

FDA approves Cablivi, first treatment for acquired thrombotic thrombocytopenic purpura
https://www.healio.com/hematology-oncology/hematology/news/online/%7Be91d83f6-8859-412b-970c-198151f0b208%7D/fda-approves-cablivi-first-treatment-for-acquired-thrombotic-thrombocytopenic-purpura
Pazdur, R.

Feb 5th, 2019 - The FDA today approved caplacizumab-yhdp injection as the first therapy specifically indicated for the treatment of adults with acquired thrombotic thrombocytopenic purpura, a rare and life-threatening blood clotting disorder.

FDA approves Cablivi® (caplacizumab-yhdp), the first Nanobody®-based medicine, for adults with acquired thrombotic thrombocytopenic purpura (aTTP)
http://hugin.info/152918/R/2233733/878824.pdf

Feb 5th, 2019 - The U.S. Food and Drug Administration (FDA) has approved Cablivi® (caplacizumab-yhdp) in combination with plasma exchange and immunosuppression for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP) in adults. Cablivi is the first FDA approved therapy specifically indicated for the treatment of aTTP.

CABLIVI (caplacizumab-yhdp) Prescribing Information
http://products.sanofi.us/cablivi/cablivi.pdf

Feb 5th, 2019 - CABLIVI is a von Willebrand factor (vWF)-directed antibody fragment indicated for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.

FDA grants orphan drug designation to APL-2 for autoimmune hemolytic anemia
https://www.healio.com/hematology-oncology/hematology/news/online/%7B2785cd04-4008-4105-91cc-e82f5573ee6f%7D/fda-grants-orphan-drug-designation-to-apl-2-for-autoimmune-hemolytic-anemia

Feb 4th, 2019 - The FDA granted orphan drug designation to the C3 complement inhibitor APL-2 for the treatment of autoimmune hemolytic anemia. Autoimmune hemolytic anemia refers to both cold agglutinin disease and warm autoimmune hemolytic anemia, which affect a combined 40,000 people in the United States and Europe.

Apellis’ APL-2 Receives Orphan Drug Designation from the FDA for the Treatment of Autoimmune Hemolytic Anemia
http://investors.apellis.com/news-releases/news-release-details/apellis-apl-2-receives-orphan-drug-designation-fda-treatment

Feb 4th, 2019 - Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat diseases through inhibition of the complement system, today announced that its C3 complement inhibitor, APL-2, has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of autoimmune hemolytic an...

FDA grants orphan drug designation to BL-8040 for pancreatic cancer
https://www.healio.com/hematology-oncology/gastrointestinal-cancer/news/online/%7B85bbf5e9-9321-4e0c-8bf0-828b7805160a%7D/fda-grants-orphan-drug-designation-to-bl-8040-for-pancreatic-cancer

Feb 3rd, 2019 - The FDA granted orphan drug designation to BL-8040 for the treatment of pancreatic cancer. BL-8040 (BioLineRx Ltd.) is a novel short peptide that functions as a high-affinity antagonist for CXCR4, according to its manufacturer. The agent is in development for treatment of solid tumors and acute myeloid leukemia, as well as for stem cell mobilization for bone marrow transplantation.

Rising cancer incidence in younger adults: is obesity to blame?
https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(19)30017-9/fulltext
Marinac, C. et. al.

Feb 2nd, 2019 - Although cancer has historically been considered a disease of aging, a reported sharp rise in colorectal cancer incidence among adults aged 54 years and younger beginning in the mid-1980s for the colon and mid-1970s for the rectum has motivated researchers to examine risk factors for early onset disease. In The Lancet Public Health, Hyuna Sung and colleagues3 report a rigorous and extensive ana...

Emerging cancer trends among young adults in the USA: analysis of a population-based cancer registry
https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(18)30267-6/fulltext
Sung, H. et. al.

Feb 2nd, 2019 - Cancer trends in younger adults, often under 50 years, reflect recent changes in carcinogenic exposures, which could foreshadow the future overall disease burden. Previous studies reported an increase in early onset colorectal cancer, which could partly reflect the obesity epidemic. We examined age-specific contemporary incidence trends in the USA for 30 common cancers, including 12 obesity-rel...

Pre-diagnostic serum concentrations of organochlorines and risk of acute myeloid leukemia: A nested case-control study in the Norwegian Janus Serum Bank Cohort.
https://www.sciencedirect.com/science/article/pii/S0160412018317562?via%3Dihub
Environment International; Bassig, B. et. al.

Feb 1st, 2019 - BACKGROUND: Epidemiologic studies suggest an increased risk of leukemia among individuals occupationally exposed to some organochlorine (OC) compounds. Associations between serum OC pesticide and polychlorinated biphenyl (PCB) levels and risk of acute myeloid leukemia (AML), the most common subtype of acute leukemia in adult populations, have not been evaluated prospectively in the general pop...

Genetics of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)
https://academic.oup.com/asj/article/39/Supplement_1/S14/5304915
Oishi, N. et. al.

Jan 30th, 2019 - Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a newly included provisional entity in the 2016 revision of the World Health Organization classification, is a distinct form of CD30-positive T-cell non-Hodgkin lymphoma that arises in association with a breast implant after reconstructive or cosmetic surgery. In addition to its characteristic clinical presentation, recent stu...

2019 NCCN Consensus Guidelines on the Diagnosis and Treatment of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)
https://academic.oup.com/asj/article/39/Supplement_1/S3/5304919
Clemens, M. et. al.

Jan 30th, 2019 - National Comprehensive Cancer Network (NCCN) guidelines represent the consensus standard of care for diagnosis and management of the majority of known cancers. NCCN guidelines on breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) have been recognized by the US Food and Drug Administration and widely advocated by national specialty societies. Consensus guidelines have helped cre...

Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura
https://www.nejm.org/doi/10.1056/NEJMoa1806311
Scully, M. et. al.

Jan 23rd, 2019 - In acquired thrombotic thrombocytopenic purpura (TTP), an immune-mediated deficiency of the von Willebrand factor–cleaving protease ADAMTS13 allows unrestrained adhesion of von Willebrand factor multimers to platelets and microthrombosis, which result in thrombocytopenia, hemolytic anemia, and tissue ischemia. Caplacizumab, an anti–von Willebrand factor humanized, bivalent variable-domain-only ...

Improved survival outcomes and restoration of graft‐vs‐leukemia effect by deferasirox after allogeneic stem cell transplantation in acute myeloid leukemia
https://onlinelibrary.wiley.com/doi/full/10.1002/cam4.1928

Jan 23rd, 2019 - Deferasirox is an oral iron‐chelating agent having possible antileukemia and immune modulatory effects. Few reports have evaluated deferasirox in the setting of allogeneic hematopoietic stem cell transplantation (allo‐HSCT). We investigated the impact of deferasirox after allo‐HSCT in acute myeloid leukemia (AML). Of 326 consecutive patients undergoing allo‐HSCT in remission, analysis of 198 pa...

Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Retrospective Multinational Study
http://ascopubs.org/doi/abs/10.1200/JCO.18.00822
Pui, C. et. al.

Jan 17th, 2019 - We determined the prognostic factors and utility of allogeneic hematopoietic cell transplantation among children with newly diagnosed hypodiploid acute lymphoblastic leukemia (ALL) treated in contemporary clinical trials. This retrospective study collected data on 306 patients with hypodiploid ALL who were enrolled in the protocols of 16 cooperative study groups or institutions between 1997 and...

Iron Deficiency Anemia - Signs and Symptoms
https://www.nhlbi.nih.gov/health-topics/iron-deficiency-anemia

Jan 17th, 2019 - Iron-deficiency anemia is a common type of anemia that occurs if you do not have enough iron in your body. People with mild or moderate iron-deficiency anemia may not have any signs or symptoms. More severe iron-deficiency anemia may cause fatigue or tiredness, shortness of breath, or chest pain.

A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease
http://www.bloodjournal.org/content/early/2019/01/17/blood-2018-08-868893?sso-checked=true
Howard, J et. al.

Jan 16th, 2019 - New treatments directly targeting polymerization of sickle hemoglobin (HbS), the proximate event in the pathophysiology of sickle cell disease (SCD), are needed to address the severe morbidity and early mortality associated with the disease. Voxelotor (GBT440) is a first-in-class, oral therapy specifically developed to treat SCD by modulating the affinity of hemoglobin for oxygen, thus inhibiti...

Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura
https://www.jwatch.org/na48305/2019/01/17/caplacizumab-acquired-thrombotic-thrombocytopenic-purpura
Green, David

Jan 16th, 2019 - Patients with acquired thrombotic thrombocytopenic purpura (TTP) have von Willebrand factor (VWF)–mediated platelet aggregates that ...HERCULES Trial

Leukemia - Lab Tests Online
https://labtestsonline.org/conditions/leukemia

Jan 14th, 2019 - Provides an overview of leukemia and tests related to the diagnosis and monitoring of leukemia. Two categories of immature precursor cells produce white blood cells: myeloid cells and lymphoid cells. Myeloid cells produce red blood cells, platelets, and several white blood cells types, known as granulocytes. Granulocytes circulate in the blood and fight infections by killing and digesting bacte...

Key Statistics for Acute Myeloid Leukemia (AML)
https://www.cancer.org/cancer/acute-myeloid-leukemia/about/key-statistics.html

Jan 7th, 2019 - The American Cancer Society's most recent estimates and statistics for acute myeloid leukemia in the United States are located here.

Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era
http://ascopubs.org/doi/abs/10.1200/JCO.18.00690?journalCode=jco
Gerson, J. et. al.

Jan 6th, 2019 - In this large cohort of younger, transplantation-eligible patients with MCL, AHCT consolidation after induction was associated with significantly improved PFS but not OS after PSW analysis. Within the limitations of a retrospective analysis, our findings suggest that in younger, fit patients, AHCT consolidation may improve PFS.

The management of primary mediastinal B‐cell lymphoma: a British Society for Haematology Good Practice Paper
https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.15731
Cwynarski, K. et. al.

Jan 3rd, 2019 - Primary mediastinal B‐cell lymphoma (PMBCL) represents 2–4% of non‐Hodgkin lymphomas and, whilst previously considered to be a subtype of diffuse large B‐cell lymphoma (DLBCL), gene expression profiling data has shown it to be a separate clinicopathological entity with evidence of an overlap with classic Hodgkin lymphoma (Rosenwald et al, 2003; Savage et al, 2003). Furthermore, it is immunophen...

NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019
https://jnccn.org/view/journals/jnccn/17/1/article-p12.xml

Jan 1st, 2019 - Chronic lymphocytic leukemia (CLL) is generally characterized by an indolent disease course. Histologic transformation (also known as Richter's transformation) to more aggressive lymphomas, such as diffuse large B-cell lymphoma or Hodgkin lymphoma, occurs in approximately 2% to 10% of patients and is associated with a poor prognosis. These NCCN Guidelines Insights discuss the recommendations fo...

Leukemia - Acute Myeloid - AML: Statistics
https://www.cancer.net/cancer-types/leukemia-acute-myeloid-aml/statistics

Dec 31st, 2018 - ON THIS PAGE: You will find information about the number of people who are diagnosed with AML each year. You will also read general information on surviving the disease. Remember, survival rates depend on several factors. Use the menu to see other pages.

Initial Diagnostic Work-Up of Acute Leukemia: ASCO Clinical Practice Guideline Endorsement o...
http://ascopubs.org/doi/10.1200/JCO.18.01468
de Haas, V.

Dec 2nd, 2018 - The College of American Pathologists (CAP) and the American Society of Hematology (ASH) developed an evidence-based guideline on the initial diagnostic work-up of acute leukemia (AL). Because of the relevance of this topic to the ASCO membership, ASCO reviewed the guideline and applied a set of procedures and policies for endorsing clinical practice guidelines that have been developed by other.

Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
http://www.jnccn.org/content/16/12/1500.full
Gotlib, J.

Nov 30th, 2018 - Mastocytosis is a group of heterogeneous disorders resulting from the clonal proliferation of abnormal mast cells and their accumulation in the skin and/or in various extracutaneous organs. Systemic mastocytosis is the most common form of mastocytosis diagnosed in adults, characterized by mast cell infiltration of one or more extracutaneous organs (with or without skin involvement).

American Society of Hematology 2018 guidelines for management of venous thromboembolism: opt...
http://www.bloodadvances.org/content/2/22/3257
Witt, D.

Nov 26th, 2018 - Background: Clinicians confront numerous practical issues in optimizing the use of anticoagulants to treat venous thromboembolism (VTE). Objective: These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians and other health care professionals in their decisions about the use of anticoagulants in the management of VTE.

American Society of Hematology 2018 Guidelines for management of venous thromboembolism: tre...
http://www.bloodadvances.org/content/2/22/3292
Monagle, P.

Nov 26th, 2018 - Background: Despite an increasing incidence of venous thromboembolism (VTE) in pediatric patients in tertiary care settings, relatively few pediatric physicians have experience with antithrombotic interventions. Objective: These guidelines of the American Society of Hematology (ASH), based on the best available evidence, are intended to support patients, clinicians, and other health care profes.

American Society of Hematology 2018 guidelines for management of venous thromboembolism: dia...
http://www.bloodadvances.org/content/2/22/3226
Lim, W.

Nov 26th, 2018 - Background: Modern diagnostic strategies for venous thromboembolism (VTE) incorporate pretest probability (PTP; prevalence) assessment. The ability of diagnostic tests to correctly identify or exclude VTE is influenced by VTE prevalence and test accuracy characteristics.

American Society of Hematology 2018 guidelines for management of venous thromboembolism: hep...
http://www.bloodadvances.org/content/2/22/3360
Cuker, A.

Nov 26th, 2018 - Background: Heparin-induced thrombocytopenia (HIT) is an adverse drug reaction mediated by platelet-activating antibodies that target complexes of platelet factor 4 and heparin. Patients are at markedly increased risk of thromboembolism.

American Society of Hematology 2018 guidelines for management of venous thromboembolism: pro...
http://www.bloodadvances.org/content/2/22/3198
Schünemann, H.

Nov 26th, 2018 - Background: Venous thromboembolism (VTE) is the third most common vascular disease. Medical inpatients, long-term care residents, persons with minor injuries, and long-distance travelers are at increased risk.

American Society of Hematology 2018 guidelines for management of venous thromboembolism: ven...
http://www.bloodadvances.org/content/2/22/3317
Bates, S.

Nov 26th, 2018 - Background: Venous thromboembolism (VTE) complicates ?1. 2 of every 1000 deliveries.

NCCN Guidelines Insights: Cancer-Associated Venous Thromboembolic Disease, Version 2.2018
http://www.jnccn.org/content/16/11/1289.full
Streiff, M.

Oct 31st, 2018 - Venous thromboembolism (VTE) is common in patients with cancer and increases morbidity and mortality. VTE prevention and treatment are more complex in patients with cancer.

Household exposure to pesticides and risk of leukemia in children and adolescents: Updated systematic review and meta-analysis
https://www.sciencedirect.com/science/article/pii/S143846391830364X?via%3Dihub
International Journal of Hygiene and Environmental Health; Van Maele-Fabry, G. et. al.

Sep 25th, 2018 - A systematic search of studies published in English between January 2009 and June 2018 was conducted in MEDLINE, and a “snowball searching” was performed from the reference list of identified publications and from Web of Science citations. Risk estimates were extracted from 15 case-control studies published between 1987 and 2018. The quality of the publications was assessed by using a modified ...

Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update
http://ascopubs.org/doi/full/10.1200/JCO.18.00374
Taplitz, R. et. al.

Sep 3rd, 2018 - Antibacterial and antifungal prophylaxis is recommended for patients who are at high risk of infection, including patients who are expected to have profound, protracted neutropenia, which is defined as < 100 neutrophils/µL for > 7 days or other risk factors. Herpes simplex virus–seropositive patients undergoing allogeneic hematopoietic stem-cell transplantation or leukemia induction therapy sho...

Vitamin B12 Deficiency Evaluation
https://www.mayocliniclabs.com/it-mmfiles/Vitamin_B12_Deficiency_Evaluation.pdf

Sep 1st, 2018 - ACASM / Pernicious Anemia Cascade Testing begins with Vitamin B12 Assay, Serum

Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
http://www.jnccn.org/content/16/9/1108.full
Radich, J.

Aug 31st, 2018 - Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome (Ph), resulting from a reciprocal translocation between chromosomes 9 and 22 [t(9;22] that gives rise to a BCR-ABL1 fusion gene. CML occurs in 3 different phases (chronic, accelerated, and blast phase) and is usually diagnosed in the chronic phase.

Guideline for the Management of Clostridium Difficile Infection in Children and Adolescents ...
http://ascopubs.org/doi/full/10.1200/JCO.18.00407
Diorio, C.

Aug 31st, 2018 - The aim of this work was to develop a clinical practice guideline for the prevention and treatment of Clostridium difficile infection (CDI) in children and adolescents with cancer and pediatric hematopoietic stem-cell transplantation (HSCT) patients.

Risk Factors for Acute Myeloid Leukemia (AML)
https://www.cancer.org/cancer/acute-myeloid-leukemia/causes-risks-prevention/risk-factors.html

Aug 20th, 2018 - Certain risk factors may increase your chance of developing acute myeloid leukemia. This guide will help you learn about possible causes of acute myeloid leukemia.

Acute Myeloid Leukemia (AML) Subtypes and Prognostic Factors
https://www.cancer.org/cancer/acute-myeloid-leukemia/detection-diagnosis-staging/how-classified.html

Aug 20th, 2018 - For most types of cancer, determining the stage (extent) of the cancer is very important. The stage is based on the size of the main tumor and how far the cancer has spread. This can be helpful in predicting a person’s outlook and deciding on treatment.

Management guidelines for paediatric patients receiving chimeric antigen receptor T cell the...
https://www.nature.com/articles/s41571-018-0075-2
Mahadeo, K.

Aug 5th, 2018 - In 2017, an autologous chimeric antigen receptor (CAR) T cell therapy indicated for children and young adults with relapsed and/or refractory CD19+ acute lymphoblastic leukaemia became the first gene therapy to be approved in the USA. This innovative form of cellular immunotherapy has been associated with remarkable response rates but is also associated with unique and often severe toxicities,.

FDA Grants Approval of TIBSOVO®, the First Oral, Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH1 Mutation
http://investor.agios.com/news-releases/news-release-details/fda-grants-approval-tibsovor-first-oral-targeted-therapy-adult

Jul 19th, 2018 - Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that TIBSOVO® (ivosidenib) was granted approval from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (R/R AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mut...

TIBSOVO® (ivosidenib tablets) Prescribing Information
https://www.tibsovopro.com/pdf/prescribinginformation.pdf

Jul 19th, 2018 - TIBSOVO is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for the treatment of acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test

Waldenström’s macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment...
https://academic.oup.com/annonc/advance-article/doi/10.1093/annonc/mdy146/5046942
Kastritis, E.

Jul 4th, 2018 - Waldenström’s macroglobulinaemia (WM) is a rare disease that accounts for 1%–2% of non-Hodgkin lymphomas. The reported age-adjusted incidence rate is 3.

iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supporti...
http://www.bloodjournal.org/content/131/25/2745.long?sso-checked=true
Michael Hallek

Jun 20th, 2018 - The previous edition of the consensus guidelines of the International Workshop on Chronic Lymphocytic Leukemia (iwCLL), published in 2008, has found broad acceptance by physicians and investigators caring for patients with CLL. Recent advances including the discovery of the genomic landscape of the disease, the development of genetic tests with prognostic relevance, and the detection of minimal.

ESMO Consensus Conference on malignant lymphoma: management of ‘ultra-high-risk’ patients
https://academic.oup.com/annonc/article/29/8/1687/5040056
Hutchings, M.

Jun 18th, 2018 - The European Society for Medical Oncology (ESMO) consensus conference on malignant lymphoma was held on 20 June 2015 in Lugano, Switzerland, and included a multidisciplinary panel of 25 leading experts. The aim of the conference was to develop recommendations on critical subjects difficult to consider in detail in the ESMO Clinical Practice Guidelines.